

2023 Prostate Cancer Facts & Statistics



Nationwide Incidence Rate

1 in 8 men will be diagnosed during his lifetime 3.1M men currently diagnosed

This year in the United States...

New cases: 288,300 Deaths: 34,700

Veterans are 1.5x more likely to get prostate cancer.

African-American men are 2.1x more likely to die of prostate cancer.



Incidence Rate in New York

130.7 in every 100,000 men diagnosed 16.8 in every 100,000 men die from the disease

This year in New York...

New cases: 20390 Deaths: 1650

National Rankings by State:

#7 for prostate cancer incidence #48 for prostate cancer deaths

Source: Estimates based on 2023 data from the American Cancer Society

ZERO's Impact in New York

Patient Programs

- ZERO360 is ZERO's comprehensive patient navigation service that provides individualized case management to help patients and their families connect with financial assistance, navigate insurance, and find other kinds of support including emotional support and even transportation assistance.
- ZERO also offers peer-to-peer support through our Us TOO Support Groups and MENtor programs. We match patients and caregivers with someone who has been on a similar journey to provide ongoing, one-on-one support. We also run a nationwide network of support groups for those affected by prostate cancer.
- ZERO Connect is our online private Facebook support group where you can connect with others
 affected by prostate cancer, learn from their experiences, and ask questions to patients and loved ones
 across the country.

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. Visit our website: www.zerocancer.org

ZERO Contact:

Ali Manson, MPH Vice President, Government Relations & Advocacy ali@zerocancer.org | 202-888-9401





2023 Prostate Cancer Facts & Statistics

East Coast Metro Chapter

CDMRP Grants in New York

Year Introduced: 1997 Total Grants to Date: 359 Total Grand Awards Through FY 2021*: \$222.6M

*PCRP data for FY 2022 has not yet been posted

| Grant Recipient | Year | Amount | |
|---|------|------------|--|
| Health Research Inc Roswell Park Division | 2002 | \$14135890 | |
| Sloan Kettering Institute For Cancer Research | 2008 | \$11303943 | |
| Sloan Kettering Institute For Cancer Research | 2017 | \$8198332 | |
| Sloan Kettering Institute For Cancer Research | 2014 | \$7330349 | |
| Sloan Kettering Institute For Cancer Research | 2012 | \$6984950 | |

CDC's National Comprehensive Cancer Control Program (NCCCP) Funding in New York:

• According to the CDC, general population screening for certain cancers (e.g., prostate, skin, or ovarian cancers) has not been proven successful in lowering cancer-related deaths.2 Individuals should understand their personal risk factors and family histories and speak with health care providers about screening options. Symptom recognition and prompt follow-up can also be of benefit in detecting cancer in earlier stages (e.g. ovarian cancer). Given the uncertain benefits of population-based screening for certain cancers in average-risk individuals, individuals should make informed decisions about screening with their health care providers.

• Objective: By 2017, reduce barriers to screenings and diagnostic services for disparate populations so that there are no significant differences in screening rates and rates of invasive or late stage diagnosis by race, ethnicity, income level, education level, insurance status or geographic location.

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. Visit our website: www.zerocancer.org

ZERO Contact:

Ali Manson, MPH Vice President, Government Relations & Advocacy ali@zerocancer.org | 202-888-9401

